Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
15.64
+0.98 (6.68%)
At close: Jul 2, 2026, 4:00 PM EDT
15.96
+0.32 (2.02%)
After-hours: Jul 2, 2026, 7:17 PM EDT
Design Therapeutics Employees
Design Therapeutics had 54 employees as of March 31, 2026. The number of employees did not change since the number was last reported on December 31, 2025.
Employees
54
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,290,981
Market Cap
976.83M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 54 | 0 | - | 54 | 0 |
| Dec 31, 2025 | 54 | 0 | - | 54 | 0 |
| Dec 31, 2024 | 54 | -4 | -6.90% | 54 | 0 |
| Dec 31, 2023 | 58 | 0 | - | 58 | 0 |
| Dec 31, 2022 | 58 | 20 | 52.63% | 58 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Pharming Group | 407 |
| Kura Oncology | 260 |
| DBV Technologies | 161 |
| Janux Therapeutics | 108 |
| Lexicon Pharmaceuticals | 81 |
| Inventiva | 77 |
| Avalo Therapeutics | 33 |
DSGN News
- 4 days ago - Design Therapeutics initiates patient dosing in DT-818 trial - TheFly
- 4 days ago - Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - GlobeNewsWire
- 4 weeks ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Design Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Design Therapeutics Transcript: Status update - Transcripts
- 6 weeks ago - Design Therapeutics Press release: Status update - Filings
- 6 weeks ago - Design Therapeutics Slides: Status update - Filings